New Delhi, June 26 -- The Ministry of Health is considering stringent regulatory measures that would mandate the immediate suspension of product licenses for pharmaceutical companies found manufacturing substandard drugs.

The proposed action aims to strengthen quality control mechanisms and protect public health interests across the country, according to a report by ET.

According to government officials, the ministry plans to issue a notification requiring automatic suspension of licenses for companies whose products are classified as 'not of standard quality' by government testing laboratories.

The measure is currently under discussion with state authorities as part of broader efforts to ensure pharmaceutical manufacturing standards....